Endoscopic Ultrasound Needles Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Endoscopic Ultrasound Needles Market Trends and Insights

Growing Burden of Gastrointestinal and Pancreatic Cancers

Early-onset pancreatic cancer diagnoses have risen 2.47% annually since 2019, increasing reliance on tissue sampling for definitive staging^{[1]American Cancer Society, “Pancreatic Cancer Facts & Figures,” cancer.org}. Molecular profiling protocols now accompany most pancreatic biopsy requests, which boosts daily use of EUS needles in oncology centers. Higher sample-volume requirements favor biopsy rather than aspiration tools and reinforce hospital procurement of premium designs. The endoscopic ultrasound needles market, therefore, benefits from the oncology community’s shift toward large-core tissue retrieval. In the Asia-Pacific region, national cancer plans mirror this trend, accelerating device adoption across public hospitals.

Rising Preference for Minimally Invasive Diagnostic Procedures

CMS broadened coverage for EUS-guided fine needle aspiration and biopsy in 2024, validating the approach as cost-effective compared with open or laparoscopic biopsies^{[2]Centers for Medicare & Medicaid Services, “National Coverage Determinations,” cms.gov}. Clinical evidence shows a single EUS pass can achieve histological confirmation that once required multiple surgical attempts, cutting anesthesia exposure and recovery time. Ambulatory surgical centers report higher patient satisfaction scores and stronger profit margins when using streamlined outpatient EUS workflows. These factors collectively stimulate procurement budgets, sustaining near-term growth in the Endoscopic Ultrasound Needles market. Manufacturers are therefore prioritizing compact systems tailored to outpatient settings.

Increasing Geriatric Population with Comorbidities

Adults aged 65 and older represent 67% of pancreatic cancer cases and often cannot tolerate surgical biopsies due to cardiovascular risk^{[3]National Cancer Institute, “Cancer Stat Facts,” cancer.gov}. Conscious-sedation EUS procedures mitigate anesthesia-related complications while maintaining a high diagnostic yield. Ambulatory clinics offer geriatric-friendly scheduling and same-day discharge, both of which are attractive to older patients managing multiple disorders. This demographic alignment boosts procedure volumes and stable demand for single-use, ultra-fine needles. Over the long term, aging societies in Europe and Japan ensure a durable base for the endoscopic ultrasound needles market.

Integration of AI-Guided Targeting Systems in EUS Platforms

Machine learning algorithms now achieve 94% accuracy in pancreatic mass detection, compared to 78% for conventional imaging. Real-time lesion mapping reduces repeat procedures and drives first-pass success beyond 90%. Hospitals upgrading imaging stacks inevitably refresh compatible biopsy tools, expanding high-margin needle sales. Vendors integrating predictive software and proprietary tip designs create closed ecosystems, which deepen client lock-in and lift replacement cycles across the endoscopic ultrasound needles market.

Shortage of Skilled Endoscopic Ultrasound Operators

Fewer than 15% of practicing gastroenterologists perform advanced EUS, limiting daily capacity in both urban and rural centers. Training requires 150–200 mentored cases, a hurdle for hospitals with thin specialist rosters. Asia-Pacific health systems build new cancer institutes faster than they can train operators, which caps near-term installations despite equipment subsidies. Private teaching partnerships and tele-proctorship programs aim to narrow the skills gap, but the shortage remains a long-tail restraint on the Endoscopic Ultrasound Needles market.

High Cost of Premium Biopsy Needles and Reusable Accessories

Next-generation Fork-Tip or Franseen needles cost three to four times more than standard lancet models, and strict infection-control rules forbid reuse. Budget-sensitive hospitals in Latin America and certain parts of Asia often restrict premium products to a small subset of reimbursed patients, opting for more affordable cytology tools for routine work. Ambulatory centers must balance device spend against tight payer contracts, which slows penetration of high-end designs. Persistent price pressure therefore tempers overall value growth of the endoscopic ultrasound needles market, even as unit volumes climb.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type – Biopsy Needles Drive Market Evolution

Biopsy needles held a 57.84% market share of the endoscopic ultrasound needles market in 2025, reflecting oncologists’ demand for intact core tissue that enables comprehensive molecular profiling. Their 8.29% CAGR through 2031 outpaces aspiration tools as personalized medicine protocols standardize across cancer centers. The endoscopic ultrasound needles market benefits from this structural shift, with biopsy instruments commanding premium pricing against stable year-on-year volume growth.

Aspiration needles retain their value for rapid on-site cytology, particularly in community settings without access to molecular labs. Yet the widening tissue requirements of pancreatic, biliary, and bronchial oncology place a growing ceiling on cytology-only devices. Established vendors leverage FDA 510(k) pathways to deploy iterative enhancements that maintain regulatory compliance while boosting diagnostic yield.

By Needle Gauge – Ultra-Fine Precision Gains Momentum

The 22 G gauge provided the largest contribution at 28.22% in 2025, balancing core volume with manageable bleeding risk. However the 25 G category shows a 7.41% CAGR through 2031, winning adoption for delicate pancreatic and pediatric cases where minimal trauma is paramount. Endoscopic Ultrasound Needles market size for 25 G solutions is projected to expand steadily as nitinol alloys allow thinner walls yet maintain lumen integrity.

Larger 19 G products support demanding genomic studies at academic centers, although slower growth keeps them niche. Gauge selection remains tightly linked to FDA validation protocols that test each diameter for tensile strength and biocompatibility.

By Tip Design – Fork-Tip Innovation Reshapes Sampling Efficiency

Franseen tips controlled 30.05% share in 2025, but Fork-Tip designs post the highest 7.08% CAGR to 2031. Comparative trials demonstrate higher intact-core rates and fewer passes per case, which aligns with payer pressure to shorten procedure time. The endoscopic ultrasound needles market therefore responds with rapid product cycles emphasizing proprietary cutting surfaces.

Lancet and side-beveled tools remain relevant for hyper-vascular lesions where controlled entry reduces hemorrhage risk. Collaborative R&D between STARmed and Olympus illustrates the strategic value of pairing surface metallurgy with ergonomics to protect share in this competitive arena.

By Application – Bronchial Sampling Emerges as Growth Driver

Pancreatic lesions accounted for 28.52% of global procedures in 2025, confirming the organ’s ongoing diagnostic challenge. Yet bronchial and mediastinal indications are clocking an 8.62% CAGR as pulmonologists adopt EUS-bronchoscope hybrids for lung cancer staging. Endoscopic Ultrasound Needles market size in thoracic oncology thus expands beyond classical gastroenterology.

Biliary strictures and gastrointestinal wall masses add diversified volume, supported by 2024 American College of Gastroenterology guidelines that endorse EUS biopsy for indeterminate biliary narrowing.

By Material – Nitinol Innovation Challenges Steel Dominance

Stainless steel held 59.86% share in 2025 due to cost advantages and well-understood mechanical behavior. Nitinol grows at 7.38% CAGR by offering flexibility and shape memory that preserve tip sharpness through multiple passes. Endoscopic ultrasound needles market share for nitinol climbs fastest in centers that tackle tortuous anatomy such as pancreatic tail lesions.

ISO 13485 quality frameworks guide alloy consistency, corrosion resistance, and manufacturing traceability, building clinician trust in these premium devices.

By End User – Ambulatory Centers Capture Market Momentum

Hospitals retained a 42.98% share in 2025, but ambulatory surgical centers posted a robust 8.74% CAGR through 2031. Medicare reimbursement parity and consumer preference for outpatient care boost procedure migration. The endoscopic ultrasound needles market size within ambulatory centers is expected to expand as compact cart-based EUS platforms become more prevalent in suburban clinics.

Specialty cancer clinics leverage high throughput to negotiate bulk prices, sustaining demand for single-use needles that avoid reprocessing overhead. Device makers now tailor packaging and accessory kits for same-day discharge workflows, strengthening their positioning with facility administrators.

Geography Analysis

North America generated 41.95% of global revenue in 2025, buoyed by CPT codes 43238 and 43242 that secure reimbursement in both hospital and ambulatory settings. Academic networks funnel constant clinical trials, which accelerates early adoption of AI-guided targeting and nitinol needles. Canadian centers follow U.S. protocols, while Mexican medical tourism funnels additional volumes from uninsured U.S. patients seeking lower procedure costs.

Asia-Pacific records the fastest 7.29% CAGR, driven by government oncology initiatives, growing specialist training pipelines, and urban hospital expansion. China’s cancer screening plan funds EUS suites in provincial centers, while Japan’s aging demographics propel demand for gentler diagnostics. Private hospitals in India add premium EUS services for overseas patients, broadening the endoscopic ultrasound needles market footprint. Diverse regulatory regimes require tailored submissions, but recent alignment of China’s National Medical Products Administration with ISO standards eases entry for global brands.

Europe exhibits steady growth anchored in evidence-based guidelines and well-funded universal healthcare. Germany, the United Kingdom, and France lead installations, often pairing high-end needles with AI-assisted imaging upgrades. Southern Europe trails slightly yet benefits from EU Medical Device Regulation harmonization, which streamlines purchasing decisions. Real-world evidence programs across university hospitals further validate performance claims, reinforcing clinician confidence in new designs.

Regulatory Landscape

Endoscopic ultrasound (EUS) needles are predominantly regulated as Class II medical devices in the United States, with market entry commonly supported through the FDA 510(k) premarket notification route and alignment to recognized consensus standards for biocompatibility and performance. Recent clearances under this pathway continue to refresh competition, including FDA clearance for Cook Ireland, Ltd. EchoTip AcuCore EUS Biopsy Needle (K241209) in July 2024.

In Europe, compliance is shaped by Regulation (EU) 2017/745 (EU MDR) and the progressive operationalization of EUDAMED. Following the European Commission Decision (EU) 2025/2371 confirming functionality of key EUDAMED modules in November 2025, four modules (Actor registration, UDI/Device registration, Notified Bodies and Certificates, and Market surveillance) became mandatory as of May 28, 2026, increasing the importance of accurate device and economic-operator registrations for ongoing commercialization. Biological evaluation expectations also tightened with ISO 10993-1:2025, which was published in November 2025 and later recognized by the FDA as a consensus standard, reinforcing cross-market alignment on biocompatibility evidence packages.

Value Chain Analysis

The value chain for endoscopic ultrasound needles spans specialty alloy and polymer inputs (notably stainless steel and nitinol), precision component fabrication, assembly, sterilization, packaging, and distribution through direct sales and channel partners into hospitals, ambulatory surgical centers, and specialty clinics. Major participants such as Boston Scientific, Olympus, Cook Medical, and Medtronic compete not only on tip geometry and gauge breadth but also on dependable, high-throughput micro-manufacturing and inspection systems, as even small defects can become clinically relevant during tissue acquisition.

Recent field actions highlight how quality and supply continuity influence procurement and switching decisions in this category. Olympus initiated a voluntary global removal in September 2025 for certain ViziShot 2 FLEX (19G) EBUS-TBNA needles manufactured prior to May 12, 2025, citing manufacturing inspection failures, and expanded the removal in January 2026 to all lots due to reports of component detachment during procedures. Cook Medical also implemented a field safety corrective action in April 2024 for certain EchoTip Ultra HD and EchoTip Ultra needles related to elevated bacterial endotoxin levels. These events reinforce the role of sterilization validation, endotoxin control, incoming-material qualification, and automated inspection as critical value-chain differentiators, alongside bundled ecosystem selling where needles are purchased in conjunction with proprietary endoscopic ultrasound platforms and accessories.

Market Opportunities and Future Outlook

A clear opportunity sits in premium single-use fine needle biopsy (FNB) devices that improve core tissue capture while navigating tortuous anatomy, aligning with oncology-driven requirements for intact tissue suitable for molecular profiling. Olympus moved this theme forward with its January 2026 U.S. launch of the SecureFlex single-use FNB device, emphasizing a nitinol-based design and availability across 19G, 22G, and 25G sizes. Product roadmaps that combine nitinol flexibility with differentiated cutting geometries and enhanced ultrasound visibility address first-pass success and procedure-time pressure in both hospitals and ambulatory settings.

Platform-adjacent device extensions also broaden whitespace in EUS accessory portfolios. In June 2026, Boston Scientific received FDA 510(k) clearance (K260428) for the RIVOS EUS Access Device under product code ODG, underlining continued investment in procedure-enabling accessories that can be bundled alongside needles and scopes. Separately, published clinical work continues to differentiate outcomes by needle design, including clinical evaluations where Franseen configurations show higher diagnostic accuracy than forward bevel designs, supporting continued commercialization focus on geometry-specific performance claims. Together, these developments point to near-term commercial focus on higher-yield tissue acquisition and accessory ecosystems, while quality-system robustness remains central due to recent removals and corrective actions impacting supply reliability.